Related Experiment Videos
Acetylation phenotype in hypertensive patients.
1Department of Clinical Pathology, Chinese Air Force General Hospital, Taipei.
Gaoxiong Yi Xue Ke Xue Za Zhi = the Kaohsiung Journal of Medical Sciences
|January 1, 1992
Summary
Genetic variations affect drug metabolism. This study found distinct slow and fast acetylator phenotypes in hypertensive patients treated with hydralazine, impacting drug efficacy and safety.
Area of Science:
- Pharmacogenetics
- Clinical Pharmacology
- Genetics
Background:
- Individual drug metabolism varies due to genetic enzyme variants.
- Hydralazine is an antihypertensive drug used in cardiovascular clinics.
- Understanding acetylation capacity is crucial for drug therapy.
Purpose of the Study:
- To investigate the polymorphic acetylation of hypertensive patients.
- To explore the relationship between acetylation phenotype and hydralazine treatment.
- To assess the potential for drug-induced lupus erythematosus.
Main Methods:
- Studied 96 hypertensive patients receiving hydralazine.
- Measured sulphamethazine (SMZ) acetylation in blood and urine.
- Determined SMZ elimination half-life (t1/2) after SMZ administration.
Main Results:
- Identified a bimodal distribution of acetylator phenotypes.
- Classified subjects into 26 slow and 70 fast acetylators.
- Established methods for phenotyping acetylator status.
Conclusions:
- Acetylation phenotype can be determined using SMZ.
- Findings may inform hydralazine therapeutic index.
- Potential to reduce drug-induced lupus erythematosus risk.